Financing ·
Biodexa Pharmaceuticals entered into a warrant inducement agreement on September 14, 2026, with an accredited holder…
BDRXBiodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals entered into a warrant inducement agreement on September 14, 2026, with an accredited holder to exercise all outstanding Series M, N, and O warrants at a reduced price of $1.05 per share. The transaction involves the exercise of 2,204,218 existing warrants, generating approximately $2.3 million in gross proceeds for the company before fees. In exchange, the holder receives two replacement Series P warrants for each exercised warrant, totaling up to 4,408,436 new ADSs with a five-year term and no price protection. The closing is expected on September 15, 2026, subject to customary conditions. Biodexa operates in the biopharmaceutical industry, developing innovative treatments for diseases such as cancer and diabetes.